Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 12/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18668954 | 1.00 | FKBP1A (0.50) | FKBP1AHSD17B10SMN1; SMN2TLR2TLR1 | |
| SCHEMBL9773156 | 0.89 | FKBP1A (0.50) | FKBP1AHSD17B10SMN1; SMN2TLR2TLR1 | |
| SCHEMBL4441024 | 0.89 | FKBP1A (0.50) | FKBP1AHSD17B10SMN1; SMN2TLR2TLR1 | |
| SCHEMBL18676059 | 0.88 | FKBP1A (0.52) | FKBP1AHSD17B10SMN1; SMN2NPC1MEN1 | |
| SCHEMBL25960272 | 0.88 | FKBP1A (0.50) | FKBP1AHSD17B10SMN1; SMN2TLR2TLR1 | |
| SCHEMBL12215284 | 0.88 | FKBP1A (0.52) | FKBP1AHSD17B10SMN1; SMN2NPC1MEN1 | |
| SCHEMBL15911990 | 0.87 | FKBP1A (0.49) | FKBP1AHSD17B10SMN1; SMN2TLR2TLR1 | |
| SCHEMBL13416713 | 0.86 | FKBP1A (0.47) | FKBP1AHSD17B10SMN1; SMN2TLR2TLR1 | |
| SCHEMBL13417161 | 0.86 | FKBP1A (0.47) | FKBP1AHSD17B10SMN1; SMN2TLR2TLR1 | |
| SCHEMBL18669850 | 0.86 | HSD17B10 (0.51) | FKBP1AHSD17B10SMN1; SMN2TLR2TLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4119539-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-01-18 | — | — | EP | disclosed |
| EP-4119539-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2023-01-18 | — | — | EP | disclosed |
| EP-3353145-B1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPHARMA LTD (KY) | 2022-09-28 | — | — | EP | disclosed |
| CN-113061089-A | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2021-05-06 | — | — | US | disclosed |
| CN-108283000-B | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-10941107-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2021-03-09 | — | — | US | disclosed |
| US-20200369598-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2020-11-26 | — | — | US | disclosed |
| US-20200369599-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2020-11-26 | — | — | US | disclosed |
| US-10774031-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2020-09-15 | — | — | US | disclosed |
| US-20200223783-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (KY) | 2020-07-16 | — | — | US | disclosed |
| US-10640451-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2020-05-05 | — | — | US | disclosed |
| US-20200039917-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2020-02-06 | — | — | US | disclosed |
| US-10457627-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | XW LABORATORIES INC. (KY) | 2019-10-29 | — | — | US | disclosed |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-07-18 | — | — | US | disclosed |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2019-06-27 | — | — | US | disclosed |
| WO-2017049470-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | XW LABORATORIES INC. (CN) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640451-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | FKBP1A 2163/4885HSD17B10 62/4885SMN1; SMN2 2384/4885 |
| US-20200369598-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB2, GABRB3, GABRB1 | FKBP1A 1849/4885HSD17B10 53/4885SMN1; SMN2 2121/4885 |
| US-10941107-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB2, GABRB3, GABRB1 | FKBP1A 1849/4885HSD17B10 53/4885SMN1; SMN2 2121/4885 |
| US-20200369599-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB2, GABRB3, GABRB1 | FKBP1A 1849/4885HSD17B10 53/4885SMN1; SMN2 2121/4885 |
| US-10457627-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | FKBP1A 2163/4885HSD17B10 62/4885SMN1; SMN2 2384/4885 |
| US-20190194120-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | FKBP1A 2163/4885HSD17B10 62/4885SMN1; SMN2 2384/4885 |
| US-20200039917-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | FKBP1A 2163/4885HSD17B10 62/4885SMN1; SMN2 2384/4885 |
| US-10774031-B2 | Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof | GABRB3, GABRB2, GABRB1 | FKBP1A 2163/4885HSD17B10 62/4885SMN1; SMN2 2384/4885 |
| US-20210130281-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB2, GABRB3, GABRB1 | FKBP1A 1849/4885HSD17B10 53/4885SMN1; SMN2 2121/4885 |
| US-20190218168-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | FKBP1A 2163/4885HSD17B10 62/4885SMN1; SMN2 2384/4885 |
| US-20200223783-A1 | PRODRUGS OF GAMMA-HYDROXYBUTYRIC ACID, COMPOSITIONS AND USES THEREOF | GABRB3, GABRB2, GABRB1 | FKBP1A 2163/4885HSD17B10 62/4885SMN1; SMN2 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.